Avastin, Lucentis Assumed Comparable In DME Absent More Data, MEDCAC Members Say
In a vote, the panel expressed little confidence in the adequacy of the available evidence on whether there are clinically meaningful differences in outcomes among the anti-VEGF agents.
You may also be interested in...
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.
The study’s sponsor, the NIH-funded Diabetic Retinopathy Clinical Research Network, highlighted the cost disparity between treatments for diabetic macular edema in a summary of the study’s purpose.